• Teriflunomide and dimethyl fumarate (DMF) have both demonstrated efficacy as oral therapies in a number of clinical trials in patients with relapsing-remitting MS [1] [2][3][4] • Comparing efficacy outcomes across clinical trials has inherent challenges. Despite these limitations, disease-modifying therapies are often informally compared on the basis of relative reductions in a specific trial endpoint (eg, annualized relapse rate [ARR]). However, such comparisons do not account for differences in patient populations across clinical studies, which can influence the interpretation of cross-study outcomes • Evidence-based medicine often utilizes approaches such as absolute risk reduction and number needed to treat (NNT) to get a fuller understanding of clinical outcomes -NNT takes into account not only the treatment effect but also the rarity of the event in question (eg, relapse); thus, a higher NNT would be expected if fewer patients experienced the event in the time period of interest • The MS population has evolved over time, with a downward trend in relapse rates.
INTRODUCTION
• Teriflunomide and dimethyl fumarate (DMF) have both demonstrated efficacy as oral therapies in a number of clinical trials in patients with relapsing-remitting MS [1] [2] [3] [4] • Comparing efficacy outcomes across clinical trials has inherent challenges. Despite these limitations, disease-modifying therapies are often informally compared on the basis of relative reductions in a specific trial endpoint (eg, annualized relapse rate [ARR] ). However, such comparisons do not account for differences in patient populations across clinical studies, which can influence the interpretation of cross-study outcomes • Evidence-based medicine often utilizes approaches such as absolute risk reduction and number needed to treat (NNT) to get a fuller understanding of clinical outcomes -NNT takes into account not only the treatment effect but also the rarity of the event in question (eg, relapse); thus, a higher NNT would be expected if fewer patients experienced the event in the time period of interest • The MS population has evolved over time, with a downward trend in relapse rates.
This may have an impact on comparing studies conducted at different points in time • Given these challenges, it has been recommended to apply 2 distinct measures of treatment efficacy -relative and absolute risk reduction (and its inverse) -in any cross-study comparison to provide a more reliable measure of comparative efficacy. 5 Here, we report the results of this analysis of teriflunomide and DMF using NNT/absolute risk reduction
OBJECTIVE
• To use a post hoc analysis to compare the NNT (the inverse of absolute differences) to prevent 1 relapse, 1 relapse leading to hospitalization, 1 relapse requiring intravenous (iv) Calculation of NNT
• The NNT to prevent 1 relapse, 1 relapse leading to hospitalization, or 1 relapse requiring treatment with iv corticosteroids was calculated from the inverse of the risk difference (absolute risk) of ARR in the placebo group (ARRp) and the active treatment group (ARRa): -NNT=1/(ARRp−ARRa) • The NNT to prevent 1 patient from experiencing disability progression was calculated using the Altman derivation, 6 taking into account the survival probabilities in the placebo and active treatment groups:
-The survival probability in the placebo group, Sc(t), is equal to 1 -the probability of disability progression confirmed for 12 weeks, and h is the hazard ratio of the active treatment group vs the placebo group • In each case, data are presented exactly as provided in the published sources.
As a consequence, there may be differences between studies and outcomes in the number of decimal places reported, which may ultimately influence the NNT calculations 
Disclaimer
Teriflunomide is approved in many countries, including the US and the European Union, for the treatment of relapsing multiple sclerosis or relapsing-remitting multiple sclerosis. This material may contain information that is outside of the approved labeling in some countries.
CONCLUSIONS
• Despite the well-established limitations of comparing outcomes across clinical trials, the use of NNT can provide additional information regarding the relative efficacy of specific therapeutic interventions 5
• Using this approach, we have demonstrated comparable NNTs for teriflunomide and DMF with respect to relapses and relapses requiring treatment with corticosteroids, despite differences in relative reductions between the 2 treatments
• For the subset of relapses that require hospitalization, teriflunomide was associated with both a greater relative risk reduction and lower NNTs than with DMF, which may indicate a potentially greater treatment effect of teriflunomide. However, it should be noted that there was a low number of such relapses in the DMF studies, which may confound comparison
• Only teriflunomide showed consistent, significant reductions in risk of disability progression in 2 phase 3 studies. Absolute risk reductions and NNTs were comparable between the 2 teriflunomide studies and DEFINE, but not CONFIRM, which had a higher NNT
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NNT to Prevent 1 Relapse Leading to Hospitalization
• The risk of relapse leading to hospitalization was significantly reduced vs placebo in both teriflunomide studies, but not in the DMF studies -The corresponding NNTs were lower in the teriflunomide studies compared with the DMF studies ( Table 3) , although any comparison should be made with caution given the lower number of relapses in the DMF studies
NNT to Prevent 1 Relapse Requiring iv Corticosteroids
• There was a significant reduction in the risk of relapse requiring treatment with iv corticosteroids for all studies compared with placebo ( Table 3 ) -The absolute risk reductions and NNTs were similar across the teriflunomide and DMF studies
NNT to Prevent 1 Patient Experiencing Sustained Accumulation of Disability
• The risk of disability progression sustained for 12 weeks was significantly reduced vs placebo by a similar magnitude (~30%) in both teriflunomide studies 1,2 and in DEFINE, 3 but not in CONFIRM 4
• Corresponding absolute risk reductions and NNTs were comparable between the 2 teriflunomide studies and DEFINE, but not CONFIRM, which had a higher NNT ( 
RESULTS

Patients
• Patient demographics and baseline disease characteristics were generally similar across all teriflunomide and DMF studies ( Table 2 ) -Some patients with progressive disease (secondary progressive MS, progressive relapsing MS) were also included in both teriflunomide studies, but not in DEFINE or CONFIRM -There was considerable range between studies in the proportion of patients receiving previous disease-modifying therapy -A greater proportion of patients in CONFIRM had gadolinium-enhancing lesions at baseline
NNT to Prevent 1 Relapse
• Teriflunomide and DMF significantly reduced the risk of relapse vs placebo in all studies; a higher relative risk reduction was observed for DMF, but similar absolute differences and, consequently, NNTs to prevent 1 relapse were observed across studies for both products (Table 3) 
